Catalyst Biosciences Inc (CBIO) Expected to Post Earnings of -$0.59 Per Share
Wall Street analysts expect Catalyst Biosciences Inc (NASDAQ:CBIO) to post earnings of ($0.59) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Catalyst Biosciences’ earnings. Catalyst Biosciences reported earnings of ($2.53) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 76.7%. The firm is expected to report its next earnings results on Thursday, August 2nd.
On average, analysts expect that Catalyst Biosciences will report full year earnings of ($3.04) per share for the current financial year, with EPS estimates ranging from ($3.42) to ($2.65). For the next fiscal year, analysts forecast that the business will post earnings of ($3.92) per share, with EPS estimates ranging from ($3.96) to ($3.87). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Catalyst Biosciences.
Catalyst Biosciences (NASDAQ:CBIO) last posted its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.59. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.23 million. Catalyst Biosciences had a negative return on equity of 39.27% and a negative net margin of 2,983.40%.
Shares of Catalyst Biosciences traded up $0.80, reaching $25.74, during trading on Monday, Marketbeat reports. 2,305 shares of the company’s stock were exchanged, compared to its average volume of 316,963. The firm has a market capitalization of $279.28 million, a PE ratio of -3.41 and a beta of 2.39. Catalyst Biosciences has a twelve month low of $3.11 and a twelve month high of $37.00.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CBIO. Ardsley Advisory Partners bought a new stake in Catalyst Biosciences in the 4th quarter valued at $205,000. Wells Fargo & Company MN lifted its position in shares of Catalyst Biosciences by 148.3% during the 1st quarter. Wells Fargo & Company MN now owns 8,940 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 5,340 shares during the period. Spark Investment Management LLC bought a new stake in shares of Catalyst Biosciences during the 1st quarter valued at $330,000. Geode Capital Management LLC bought a new stake in shares of Catalyst Biosciences during the 4th quarter valued at $379,000. Finally, Raymond James & Associates bought a new stake in shares of Catalyst Biosciences during the 4th quarter valued at $585,000. Institutional investors and hedge funds own 76.76% of the company’s stock.
About Catalyst Biosciences
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.